Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, thereby stabilizing it and upregulating its expression, consequently activating the G2/M phase of the cell cycle and driving HNSCC malignant progression (19). The gene discussed is CDC25B; the disease is head and neck squamous cell carcinoma.